Clinical Trial: NCT06360575
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | National Cancer Institute (NCI) |
| Information Provided By: | National Cancer Institute (NCI) |
| Last Update Posted: | 2026-10-19 |
Study Overview
Brief Summary
This phase II MATCH treatment trial tests how well crizotinib works to treat patients with cancers with MET exon 14 deletion genetic changes. Crizotinib is in a group of medications called tyrosine kinase inhibitors. It works by blocking enzymes that cancer cells need to grow and spread. It may also prevent the growth of new blood vessels that tumors need to grow.
Official Title
MATCH Treatment Subprotocol C2: Crizotinib in Patients With Tumors With MET Exon 14 Deletion
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Intervention / Treatment
- Procedure: Biopsy Procedure
- Procedure: Biospecimen Collection
- Drug: Crizotinib
- Procedure: Radiologic Examination
Other Study ID Numbers
- NCI-2024-01127
- NCI-2024-01127
- EAY131-C2
- EAY131-C2
- U10CA180820
Start Date (Actual)
2016-07-20
Primary Completion Date (Actual)
2022-11-15
Study Completion Date (Estimated)
2026-12-31
Enrollment (Actual)
20
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | National Cancer Institute (NCI) |
| Information Provided By: | National Cancer Institute (NCI) |
| Last Update Posted: | 2026-10-19 |
Study Overview
Brief Summary
This phase II MATCH treatment trial tests how well crizotinib works to treat patients with cancers with MET exon 14 deletion genetic changes. Crizotinib is in a group of medications called tyrosine kinase inhibitors. It works by blocking enzymes that cancer cells need to grow and spread. It may also prevent the growth of new blood vessels that tumors need to grow.
Official Title
MATCH Treatment Subprotocol C2: Crizotinib in Patients With Tumors With MET Exon 14 Deletion
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Intervention / Treatment
- Procedure: Biopsy Procedure
- Procedure: Biospecimen Collection
- Drug: Crizotinib
- Procedure: Radiologic Examination
Other Study ID Numbers
- NCI-2024-01127
- NCI-2024-01127
- EAY131-C2
- EAY131-C2
- U10CA180820
Start Date (Actual)
2016-07-20
Primary Completion Date (Actual)
2022-11-15
Study Completion Date (Estimated)
2026-12-31
Enrollment (Actual)
20
Study Type
Interventional
Phase
Phase 2